Indegene Limited has informed the Exchange about Acquisition
INDGN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Indegene Limited announced that its step-down subsidiary, Indegene Healthcare UK Limited, has signed a Share Purchase Agreement to acquire 100% of two UK-based companies: DT Associates Research and Consulting Services Limited (DT UK) and Trilogy Writing & Consulting Limited (Trilogy UK). The total cash consideration is approximately £2.7 million (£2,001,000 for DT UK and £702,348 for Trilogy UK). Both targets are in the healthcare and life sciences space, offering analytics, medical/regulatory services (DT UK) and pharmaceutical writing and training (Trilogy UK). Combined, they generated around £8.7 million in revenue in their latest financial year. The acquisition is classified as a related party transaction done at arm's length and is described as an internal restructuring. The deal is expected to close by 31 March 2026 and no government approvals are required.
This is a relatively small, tuck-in acquisition aimed at internal restructuring within the Indegene group, consolidating UK healthcare consulting entities under one subsidiary. It is unlikely to materially move the stock, but it strengthens Indegene's UK healthcare services footprint. No open offer is triggered as the acquisition is by a wholly owned subsidiary.